An NIA-funded biotech company may be one step closer to developing a blood-based diagnostic for Alzheimer’s disease. This biotech company, Amprion, recently received a Breakthrough Device Designation by the FDA for a test developed to detect the alpha-synuclein protein in the cerebrospinal fluid and bloodstream, a known biomarker for Parkinson’s disease. Such designation by the FDA paves the way for faster development, assessment, and review, and potentially FDA approval of the technology. Small Business grants from the NIA are enabling Amprion to adopt their test to specifically detect traces of two biomarkers for Alzheimer’s disease, amyloid and tau aggregates, in cerebrospinal fluid and the bloodstream. With this new FDA designation for their technology, this company may be on track to develop a test that could help facilitate early detection and diagnosis of these devasting diseases.
The Friends of the National Institute on Aging has sent a letter to President Obama requesting an increase of $500 million to support biomedical, behavioral and social sciences aging research efforts at the National Institutes of Health for fiscal year 2016.
It is available here:
FONIA final FY 2016 OMB
Members of the Friends of the National Institute on Aging have sent a letter to President Obama requesting an increase of $500 million to support biomedical, behavioral and social sciences aging research efforts at the National Institutes of Health for fiscal year 2016.
The letter points out that the 65 and older population is expected to double between 2010 and 2050. This will come with an increase in the prevalence of diseases disproportionately affecting older people, most notably Alzheimer’s disease.
With this added investment, however, the NIH can:
- Implement new prevention and treatment clinical trials, research training initiatives, care interventions, and genetic research studies developed to meeting the goals of the National Plan to Address Alzheimer’s disease.
- Bolster trans-NIH initiatives developed by the NIH GeroScience Interest Group to understand basic cellular and molecular underpinnings of aging as a principal risk factor for chronic disease and to explore common mechanisms governing relationships between aging and chronic disease.
- Understand the impact of economic concerns on older adults by examining work and retirement behavior, health and functional ability, and policies that influence individual well-being.
- Support family caregivers by enhancing physician-family communication during end-of-life and critical care.
To read the letter, please click on the link below:
FONIA final FY 2016 OMB
Time: November 8, 2011 from 10am to 11am
Location: SVC 203-202 (Capitol Visitor’s Center)
Event Type: congressional, briefing
Organized By: Alzheimer’s Association
The Alzheimer’s Association invites you to a briefing on:
“Alzheimer’s from the Frontlines: Challenges a National Alzheimer’s Plan Must Address”
Tuesday, November 8, 2011 from 10 A.M. to 11 A.M.
SVC 203-202 (Capitol Visitors Center)
Please join us for a Congressional Briefing unveiling an important new report, “Alzheimer’s from the Frontlines: Challenges a National Alzheimer’s Plan Must Address.” This report offers insights and perspectives from the Alzheimer’s community on ten critical challenges the first ever National Alzheimer’s Plan must address. The National Alzheimer’s Project Act (P.L. 111-375), unanimously passed by Congress last year, requires the creation of a National Alzheimer’s Plan to address the rapidly mounting Alzheimer’s disease crisis and will coordinate Alzheimer’s disease efforts across the federal government.
Building on the Association’s commitment to provide a platform for those directly affected by Alzheimer’s, the Association and its more than 70 chapters nationwide hosted over 130 input sessions throughout the country, allowing thousands of individuals to speak on behalf of all Americans counting on this effort to change the trajectory of this devastating disease for the millions affected today and the millions more at risk tomorrow. “Alzheimer’s from the Frontlines” provides a rare and unique window into the real, unrelenting challenges the disease forces on families year after year.
- Harry Johns, President and CEO, Alzheimer’s Association
- Robert Egge, Vice President of Public Policy, Alzheimer’s Association
- Garrett Davis, Alzheimer’s Association Ambassador
- Senator Susan Collins (R- ME) (invited)
- Senator Mark Warner (D-VA) (invited)
- Senator Richard Burr (R-NC) (invited)
- Senator Debbie Stabenow (D-MI) (invited)
Please RSVP to Tonya Buford at [email protected]
The Alzheimer’s Association is the world’s leading voluntary health organization in Alzheimer care, support and research. Our mission is to eliminate Alzheimer’s disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer’s. For more information, visit www.alz.org
Posted by Kimberly Acquaviva, PhD, MSW on November 10, 2010 at 12:22pm
Dear Friends of the National Institute on Aging,
I wanted to let you know about an upcoming event that may be of interest to you, your colleagues, and your constituents. On Thursday, November 18th, Friends of the NIA is co-sponsoring two educational briefings (one House and one Senate), titled “Leading the Way on Alzheimer’s Disease and Aging Research: A briefing about the vital work of the National Institute on Aging. The event is jointly sponsored by the Alliance for Aging Research, Alzheimer’s Foundation of America, Cure Alzheimer’s Fund, Friends of the NIA, and Leaders Engaged on Alzheimer’s Disease (LEAD). Links are provided below for the flyers for both the House and Senate briefings, listing time and location as well as confirmed speakers.
Please feel free to disseminate these flyers through your listservs, websites, etc. Any assistance you could provide in helping to spread the word about this exciting event would be greatly appreciated. To RSVP for either briefing, please send an email to [email protected] confirming your plans to attend.